Professional Summary »
Specializing In »
Practice Locations »
Referring Physicians »
Specializing In
- Cancer Immunotherapy
- Cellular Therapy
- Radiation oncology
- Sarcoma
- Solid Tumors
Biography
Dr. Kalbasi is a board-certified radiation oncologist and physician-scientist at the Stanford Cancer Institute. He is also an associate professor of radiation oncology at Stanford Medicine and a project member of the Parker Institute for Cancer Immunotherapy.
In the clinic, Dr. Kalbasi specializes in the diagnosis and treatment of solid tumors, especially sarcoma and melanoma, with a focus on bringing new treatments to patients. This focus includes using advanced techniques in radiation oncology and cancer immunotherapy.
Dr. Kalbasi's NIH-funded laboratory studies the cancer-immune interface in various therapeutic contexts, including T cell therapy, cytokine therapy and innate immune agonism. The lab has described tumor cell-, T cell- and myeloid cell-intrinsic mechanisms of resistance to therapy and approaches to overcome therapy resistance. Dr. Kalbasi is also an experienced leader of clinical trials related to immunotherapy, T cell therapy and radiation therapy.
Prior to his arrival at Stanford Health Care, Dr. Kalbasi was assistant professor of radiation oncology in the David Geffen School of Medicine at UCLA and chief of sarcoma radiotherapy at the UCLA Jonsson Comprehensive Cancer Center. During his tenure, he was named a NextGen Star by the American Association of Cancer Research in recognition for excellence in cancer research.
Dr. Kalbasi’s work has been published in leading journals including Nature, Science Translational Medicine, JAMA Oncology, Lancet Oncology, Nature Cancer and Cancer Discovery. He has served as a peer reviewer for multiple prestigious journals, including the Proceedings of the National Academy of Sciences, Cell and the Journal of Clinical Investigation. He has also presented research to his peers at the American Association for Cancer Research and the American Institute of Chemical Engineers.
In the clinic, Dr. Kalbasi specializes in the diagnosis and treatment of solid tumors, especially sarcoma and melanoma, with a focus on bringing new treatments to patients. This focus includes using advanced techniques in radiation oncology and cancer immunotherapy.
Dr. Kalbasi's NIH-funded laboratory studies the cancer-immune interface in various therapeutic contexts, including T cell therapy, cytokine therapy and innate immune agonism. The lab has described tumor cell-, T cell- and myeloid cell-intrinsic mechanisms of resistance to therapy and approaches to overcome therapy resistance. Dr. Kalbasi is also an experienced leader of clinical trials related to immunotherapy, T cell therapy and radiation therapy.
Prior to his arrival at Stanford Health Care, Dr. Kalbasi was assistant professor of radiation oncology in the David Geffen School of Medicine at UCLA and chief of sarcoma radiotherapy at the UCLA Jonsson Comprehensive Cancer Center. During his tenure, he was named a NextGen Star by the American Association of Cancer Research in recognition for excellence in cancer research.
Dr. Kalbasi’s work has been published in leading journals including Nature, Science Translational Medicine, JAMA Oncology, Lancet Oncology, Nature Cancer and Cancer Discovery. He has served as a peer reviewer for multiple prestigious journals, including the Proceedings of the National Academy of Sciences, Cell and the Journal of Clinical Investigation. He has also presented research to his peers at the American Association for Cancer Research and the American Institute of Chemical Engineers.
View Full Biography »
Professional Summary
Education & Certifications
- Board Certification: American Board of Radiology, Radiation Oncology (2017)
- Residency: University of Pennsylvania Radiation Oncology Program (2016) PA
- Internship: University of Pennsylvania Internal Medicine Residency (2012) PA
- Medical Education: UCLA David Geffen School Of Medicine Registrar (2011) CA
- B.S., UCLA, Biochemistry
- M.D., David Geffen School of Medicine at UCLA, Medicine
- Board Certification, American Board of Radiology, Radiation Oncology
Honors & Awards
- AACR NextGen Star Award, American Association for Cancer Research
- Alpha Omega Alpha, David Geffen School of Medicine at UCLA
- ASCO Merit Award, Conquer Cancer Foundation
- ASCO Young Investigator Award, Conquer Cancer Foundation
- Clinical Scientist Career Development Award (K08), National Cancer Institute
- Damon Runyon Clinical Investigator Award, Damon Runyon Cancer Research Foundation
- Geffen Scholar, David Geffen School of Medicine
- HHMI Research Scholar, Howard Hughes Medical Institute
- Joseph Drown Foundation Dean's Award in Research Excellence, UCLA
- Merck Index Award, UCLA Dept. of Chemistry & Biochemistry
- MRA Young Investigator Award, Melanoma Research Alliance
- Phi Beta Kappa, UCLA
- Regents' Scholar, UCLA
- Robert C. Byrd Scholar, U.S. Dept. of Education
- Robert L. and Mary Ellenburg Endowed Faculty Scholar, Stanford University School of Medicine
- SARC Career Enhancement Award, Sarcoma Alliance for Research through Collaboration
- SITC Young Investigator Award, Society for Immunotherapy of Cancer
- Tower Cancer Research Foundation Young Investigator Award, Tower Cancer Research Foundation
Publications
-
(99)mTc-phytate as a diagnostic probe for assessing inflammatory reaction in malignant tumors
Fernandes, R. S., Mota, L. G., Kalbasi, A., Moghbel, M., Werner, T. J., Alavi, A., … de Barros, A. L. B. (2015). (99)mTc-phytate as a diagnostic probe for assessing inflammatory reaction in malignant tumors. NUCLEAR MEDICINE COMMUNICATIONS, 36(10), 1042–48. -
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
Ribas, A., Medina, T., Kummar, S., Amin, A., Kalbasi, A., Drabick, J. J., … Janssen, R. S. (2018). SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. CANCER DISCOVERY, 8(10), 1250–57. -
Orthogonal IL-9 receptor signaling reprograms T cells to obviate conditioning chemotherapy before adoptive cell therapy.
Kalbasi, A., Tariveranmoshabad, M., Escuin-Ordenas, H., Kremer, S., Su, L. L., Picton, L., … Ribas, A. (2021). Orthogonal IL-9 receptor signaling reprograms T cells to obviate conditioning chemotherapy before adoptive cell therapy. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Potentiating adoptive cell therapy using synthetic IL-9 receptors.
Kalbasi, A., Siurala, M., Su, L. L., Tariveranmoshabad, M., Picton, L. K., Ravikumar, P., … Garcia, K. C. (2022). Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature. -
Engineered IL13 variants direct specificity of IL13Ra2-targeted CAR T cell therapy.
Stern, L. A., Gholamin, S., Moraga, I., Yang, X., Saravanakumar, S., Cohen, J. R., … Brown, C. E. (2022). Engineered IL13 variants direct specificity of IL13Ra2-targeted CAR T cell therapy. Proceedings of the National Academy of Sciences of the United States of America, 119(33), e2112006119. -
Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma.
Kalbasi, A., Tariveranmoshabad, M., Hakimi, K., Kremer, S., Campbell, K. M., Funes, J. M., … Ribas, A. (2020). Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. Science Translational Medicine, 12(565). -
A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma.
Kalbasi, A., Kamrava, M., Chu, F.-I. I., Telesca, D., Van Dams, R., Yang, Y., … Eilber, F. C. (2020). A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 26(8), 1829–1836. -
Tumour-intrinsic resistance to immune checkpoint blockade.
Kalbasi, A., & Ribas, A. (2020). Tumour-intrinsic resistance to immune checkpoint blockade. Nature Reviews. Immunology, 20(1), 25–39. -
Conserved Interferon-? Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.
Grasso, C. S., Tsoi, J., Onyshchenko, M., Abril-Rodriguez, G., Ross-Macdonald, P., Wind-Rotolo, M., … Ribas, A. (2020). Conserved Interferon-? Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell, 38(4), 500–515.e3. -
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade.
Torrejon, D. Y., Abril-Rodriguez, G., Champhekar, A. S., Tsoi, J., Campbell, K. M., Kalbasi, A., … Ribas, A. (2020). Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. Cancer Discovery, 10(8), 1140–1157. -
Lifelong Imaging Surveillance is Indicated for Patients with Primary Retroperitoneal Liposarcoma.
Eckardt, M. A., Graham, D. S., Klingbeil, K. D., Lofftus, S. Y., McCaw, T. R., Bailey, M. J., … Crompton, J. G. (2022). Lifelong Imaging Surveillance is Indicated for Patients with Primary Retroperitoneal Liposarcoma. Annals of Surgical Oncology. -
Adopting shorter radiation regimens: rules of engagement for sarcoma.
Kalbasi, A. (2023). Adopting shorter radiation regimens: rules of engagement for sarcoma. The Lancet. Oncology, 24(2), e70. -
Human chimeric orthogonal IL9 receptor signaling promotes stemness and polyfunctionality for adoptive T cell therapy of cancer
Tariveranmoshabad, M., Su, L. L., Sun, A. L., Picton, L. K., Ribas, A., Garcia, K. C., & Kalbasi, A. (2022). Human chimeric orthogonal IL9 receptor signaling promotes stemness and polyfunctionality for adoptive T cell therapy of cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Infrequent chromosomal loss and recurrent gains lead to imbalanced expression of HLA genes in melanoma
Campbell, K. M., Saco, J., Medina, E., Amouzgar, M., Pfeiffer, S. M., Gonzalez, C. R., … Ribas, A. (2022). Infrequent chromosomal loss and recurrent gains lead to imbalanced expression of HLA genes in melanoma. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Adopting shorter radiation regimens: rules of engagement for sarcoma
Kalbasi, A. (2020). Adopting shorter radiation regimens: rules of engagement for sarcoma. LANCET ONCOLOGY, 24(2), E70. -
IGF2BP3 as a Prognostic Biomarker in Well-Differentiated/Dedifferentiated Liposarcoma.
Klingbeil, K. D., Tang, J. P., Graham, D. S., Lofftus, S. Y., Jaiswal, A. K., Lin, T. L., … Kadera, B. E. (2023). IGF2BP3 as a Prognostic Biomarker in Well-Differentiated/Dedifferentiated Liposarcoma. Cancers, 15(18).
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Practice Locations
Radiation Oncology at Blake Wilbur Building Palo Alto, CA
Palo Alto, CA
Radiation Oncology at Blake Wilbur Building
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records